RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostasis in Mouse PDAC Cells
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3,...
Saved in:
Published in | Frontiers in oncology Vol. 12; p. 826617 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
24.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered
Kras
G12D
-driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the
Kras
G12D
genotype and provide novel therapeutic strategies to combat PDAC drug resistance. |
---|---|
AbstractList | Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered
Kras
G12D
-driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the
Kras
G12D
genotype and provide novel therapeutic strategies to combat PDAC drug resistance. Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered Kras G12D-driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the Kras G12D genotype and provide novel therapeutic strategies to combat PDAC drug resistance.Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered Kras G12D-driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the Kras G12D genotype and provide novel therapeutic strategies to combat PDAC drug resistance. Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered -driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the genotype and provide novel therapeutic strategies to combat PDAC drug resistance. Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA repair-redox signaling protein Ref-1 has a redox signaling function that activates several transcriptional factors (TFs) including NF-κB (RelA), STAT3, AP-1. These have been implicated in signaling in PDAC and associated with cancer progression and therapy resistance. Numerous studies have shown a role for RelA in PDAC inflammatory responses and therapy resistance, little is known as to how these inflammatory responses are modulated through Ref-1 redox signaling pathways during pancreatic pathogenesis. RelA and STAT3 are two major targets of Ref-1 and are important in PDAC pathogenesis. To decipher the mechanistic role of RelA in response to Ref-1 inhibition, we used PDAC cells (KC3590) from a genetically engineered KrasG12D-driven mouse model that also is functionally deficient for RelA (Parent/Vector) or KC3590 cells with fully functional RelA added back (clone 13; C13). We demonstrated that RelA deficient cells are more resistant to Ref-1 redox inhibitors APX3330, APX2009, and APX2014, and their sensitivity is restored in the RelA proficient cells. Knockdown of STAT3 did not change cellular sensitivity to Ref-1 redox inhibitors in either cell type. Gene expression analysis demonstrated that Ref-1 inhibitors significantly decreased IL-8, FOSB, and c-Jun when functional RelA is present. We also demonstrated that PRDX1, a known Ref-1 redox modulator, contributes to Ref-1 inhibitor cellular response. Knockdown of PRDX1 when functional RelA is present resulted in dramatically increased PDAC killing in response to Ref-1 inhibitors. The enhanced cell killing was not due to increased intracellular ROS production. Although Ref-1 inhibition decreased the NADP/NADPH ratio in the cells, the addition of PRDX1 knockdown did not further this redox imbalance. This data suggests that the mechanism of cell killing following Ref-1 inhibition is at least partially mediated through RelA and not STAT3. Further imbalancing of the redox signaling through disruption of the PRDX1-Ref-1 interaction may have therapeutic implications. Our data further support a pivotal role of RelA in mediating Ref-1 redox signaling in PDAC cells with the KrasG12D genotype and provide novel therapeutic strategies to combat PDAC drug resistance. |
Author | Mijit, Mahmut Gampala, Silpa Kelley, Mark R. Wireman, Randall Zhang, Chi Schneeweis, Christian Schneider, Guenter Fishel, Melissa L. Armstrong, Lee Hassan, Zonera |
AuthorAffiliation | 7 Department of Pharmacology and Toxicology, Indiana University School of Medicine , Indianapolis, IN , United States 8 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine , Indianapolis, IN , United States 1 Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine , Indianapolis, IN , United States 2 Department of Clinic and Polyclinic for Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich , Munich , Germany 3 Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen , Göttingen , Germany 4 Department of Medical and Molecular Genetics, Indiana University School of Medicine , Indianapolis, IN , United States 5 Department of Biohealth Informatics, Indiana University-Purdue University (IUPUI) , Indianapolis, IN , United States 9 Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University , Indianapolis, IN , United Sta |
AuthorAffiliation_xml | – name: 4 Department of Medical and Molecular Genetics, Indiana University School of Medicine , Indianapolis, IN , United States – name: 8 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine , Indianapolis, IN , United States – name: 9 Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University , Indianapolis, IN , United States – name: 1 Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine , Indianapolis, IN , United States – name: 7 Department of Pharmacology and Toxicology, Indiana University School of Medicine , Indianapolis, IN , United States – name: 6 Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine , Indianapolis, IN , United States – name: 3 Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen , Göttingen , Germany – name: 5 Department of Biohealth Informatics, Indiana University-Purdue University (IUPUI) , Indianapolis, IN , United States – name: 2 Department of Clinic and Polyclinic for Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich , Munich , Germany |
Author_xml | – sequence: 1 givenname: Mahmut surname: Mijit fullname: Mijit, Mahmut – sequence: 2 givenname: Randall surname: Wireman fullname: Wireman, Randall – sequence: 3 givenname: Lee surname: Armstrong fullname: Armstrong, Lee – sequence: 4 givenname: Silpa surname: Gampala fullname: Gampala, Silpa – sequence: 5 givenname: Zonera surname: Hassan fullname: Hassan, Zonera – sequence: 6 givenname: Christian surname: Schneeweis fullname: Schneeweis, Christian – sequence: 7 givenname: Guenter surname: Schneider fullname: Schneider, Guenter – sequence: 8 givenname: Chi surname: Zhang fullname: Zhang, Chi – sequence: 9 givenname: Melissa L. surname: Fishel fullname: Fishel, Melissa L. – sequence: 10 givenname: Mark R. surname: Kelley fullname: Kelley, Mark R. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35402225$$D View this record in MEDLINE/PubMed |
BookMark | eNp1UstuEzEUHaEiWkr3rJCXbJKOHzPxbJCiNNBIBapQJHbWHftO4mpiB9tB8GH8H56kVCkS9sL29XlYx_dlceK8w6J4Tcsx57K57LzTY1YyNpasrunkWXHGGBejRvBvJ0f70-Iixvsyj7oqaclfFKe8EpnHqrPi9xL7KVlEAo7MY0SXLPTkDsIKE-l8IHO3BqetW5EZ9v2uh0CWGLfeRYwkeZLWSK4-TXNxCzZcLrEb0Xww_if5YlcO-oF6G3xC67KJGdjJh30VQ9qFFhKaY_GBeu036GOCaCPJvI9-F5HcXk1ne2B8VTzvoI948bCeF1_fz-9m16Obzx8Ws-nNSIuapZEuDa2BUo2iqicCKglUoikNIMqWV8wwwbATDTZS1poKyFMAl2zSsq5Gfl4sDrrGw73aBruB8Et5sGpf8GGlICSre1SN1G3JjOZGcsEmdLBoeDWBqu2qxrCs9e6gtd21GzQ6Rx2gfyL69MbZtVr5H0rmx1HeZIG3DwLBf9_lFNXGRp3jAIc5H8Vq0bCqZg3P0DfHXo8mf_89A8oDQAcfY8DuEUJLNXSXGrpLDd2lDt2VKfU_FG0TJOuH19r-_8Q_YxfWyw |
CitedBy_id | crossref_primary_10_1016_j_compbiomed_2024_109395 crossref_primary_10_3390_ijms24021101 crossref_primary_10_1590_1414_431x2024e13250 crossref_primary_10_3389_fmed_2023_1146115 crossref_primary_10_1002_mc_23512 crossref_primary_10_3390_ijms24043251 |
Cites_doi | 10.1186/s13046-021-02046-x 10.1128/MCB.24.17.7806-7819.2004 10.3390/ijms221910279 10.1074/jbc.M114.621995 10.1016/j.drudis.2020.10.015 10.1002/1878-0261.12138 10.1093/ibd/izaa161 10.1007/s00018-010-0488-2 10.1038/s41416-021-01270-8 10.1186/s13046-020-01686-9 10.3390/ijms19123890 10.18632/oncotarget.23493 10.1038/srep29389 10.1021/jm201537d 10.1371/journal.pone.0070909 10.1172/JCI86477 10.1172/JCI29882 10.3390/cancers13184510 10.2174/1874467211205010036 10.1124/jpet.118.248088 10.1038/s41392-021-00641-0 10.1073/pnas.1703096114 10.3389/fcell.2021.731588 10.1021/bi400179m 10.1016/j.cytogfr.2009.11.005 10.1016/j.stem.2018.10.013 10.1038/s41401-020-00584-2 10.1158/1078-0432.CCR-13-1664 10.1038/s41467-021-21736-w 10.1016/j.ccr.2011.12.006 10.1089/107999099313866 10.33696/Signaling.2.044 10.1111/jcmm.16132 10.1158/1535-7163.MCT-18-1166 10.1158/1078-0432.CCR-08-1539 10.1002/ijc.27916 10.1089/ars.2010.3410 10.1089/ars.2008.2120 10.4251/wjgo.v12.i2.173 10.1039/9781839162541-00286 10.1093/nar/gkn416 10.18632/oncotarget.23897 10.18060/22794 10.1021/bi201034z 10.1021/jm9014857 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley. Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley |
Copyright_xml | – notice: Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley. – notice: Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fonc.2022.826617 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals - May need to register for free articles |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2234-943X |
ExternalDocumentID | oai_doaj_org_article_98cb02dc3d834271aee89357a5bf59d2 PMC8988139 35402225 10_3389_fonc_2022_826617 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NEI NIH HHS grantid: R01 EY031939 – fundername: NHLBI NIH HHS grantid: U01 HL143403 – fundername: NCI NIH HHS grantid: R01 CA211098 – fundername: NCI NIH HHS grantid: P30 CA082709 – fundername: NCI NIH HHS grantid: R01 CA167291 – fundername: NHLBI NIH HHS grantid: R01 HL140961 – fundername: NCI NIH HHS grantid: R01 CA231267 – fundername: NCI NIH HHS grantid: R01 CA254110 – fundername: NCI NIH HHS grantid: R01 CA205166 – fundername: ; – fundername: ; grantid: NF180045 – fundername: ; grantid: HL140961, HL143403 – fundername: ; grantid: EY031939 – fundername: ; grantid: CA167291, CA254110, CA205166, CA231267, CA211098, P30CA08270 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c462t-c0d16a11ce45674a58a18ed0daee8b352d242ef49e9886c14a4a44a3827b2f6e3 |
IEDL.DBID | M48 |
ISSN | 2234-943X |
IngestDate | Wed Aug 27 01:32:30 EDT 2025 Thu Aug 21 18:12:49 EDT 2025 Fri Jul 11 07:34:41 EDT 2025 Thu Jan 02 22:24:00 EST 2025 Thu Apr 24 22:56:34 EDT 2025 Tue Jul 01 02:46:31 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | redox signaling Ape1 pancreatic ductal adenocarcinoma (PDAC) PRDX1 STAT3 transcriptional factors DNA repair relA |
Language | English |
License | Copyright © 2022 Mijit, Wireman, Armstrong, Gampala, Hassan, Schneeweis, Schneider, Zhang, Fishel and Kelley. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c462t-c0d16a11ce45674a58a18ed0daee8b352d242ef49e9886c14a4a44a3827b2f6e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors share senior authorship This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology Edited by: Michael Weinfeld, University of Alberta, Canada Reviewed by: Dindial Ramotar, Hamad bin Khalifa University, Qatar; Bruce Demple, Stony Brook University, United States; Lynn Harrison, Louisiana State University Health Shreveport, United States |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2022.826617 |
PMID | 35402225 |
PQID | 2649256293 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_98cb02dc3d834271aee89357a5bf59d2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8988139 proquest_miscellaneous_2649256293 pubmed_primary_35402225 crossref_primary_10_3389_fonc_2022_826617 crossref_citationtrail_10_3389_fonc_2022_826617 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-03-24 |
PublicationDateYYYYMMDD | 2022-03-24 |
PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-24 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in oncology |
PublicationTitleAlternate | Front Oncol |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Gujral (B9) 2017; 114 Wu (B7) 2021; 6 Luo (B34) 2008; 10 Fishel (B40) 2014; 290 Gong (B10) 2014; 20 Silke (B4) 2021; 13 Hu (B3) 2021; 42 Grivennikov (B8) 2010; 21 Pramanik (B6) 2018; 19 Zhang (B39) 2013; 52 Gampala (B14) 2020 Brennan (B44) 2020; 39 Shah (B24) 2017; 11 Wilson (B26) 2010; 67 Roebuck (B42) 1999; 19 Fujioka (B30) 2004; 24 Cai (B45) 2018; 23 Caston (B28) 2021; 25 Curtis Heisel (B11) 2021; 2 Cesaratto (B17) 2013; 8 Oliveira (B19) 2021; 9 Kelley (B36) 2011; 14 Mendonca (B32) 2018; 1 Wang (B43) 2018; 9 Sahakian (B46) 2020; 27 Ischenko (B2) 2021; 12 Conradt (B23) 2013; 132 Jedinak (B33) 2011; 31 Algül (B22) 2007; 117 Gampala (B25) 2021; 40 Caston (B13) 2021; 26 Rai (B27) 2012; 55 Gampala (B20) 2021; 124 Kelley (B12) 2012; 5 McIlwain (B18) 2018; 9 Ling (B5) 2012; 21 Fishel (B29) 2015; 290 Nassour (B15) 2016; 6 Sarantis (B1) 2020; 12 Pan (B31) 2008; 14 Luo (B38) 2012; 51 Ando (B16) 2008; 36 Sardar Pasha (B37) 2018; 367 Fishel (B41) 2019; 18 Nyland (B35) 2010; 53 Lesina (B21) 2016; 126 Hartman (B47) 2021; 22 |
References_xml | – volume: 40 start-page: 251 year: 2021 ident: B25 article-title: Ref-1 Redox Activity Alters Cancer Cell Metabolism in Pancreatic Cancer: Exploiting This Novel Finding as a Potential Target publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-021-02046-x – volume: 24 year: 2004 ident: B30 article-title: NF-kappaB and AP-1 Connection: Mechanism of NF-kappaB-Dependent Regulation of AP-1 Activity publication-title: Mol Cell Biol doi: 10.1128/MCB.24.17.7806-7819.2004 – volume: 22 start-page: 10279 year: 2021 ident: B47 article-title: Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy publication-title: Int J Mol Sci doi: 10.3390/ijms221910279 – volume: 290 year: 2014 ident: B40 article-title: Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2 publication-title: J Biol Chem doi: 10.1074/jbc.M114.621995 – volume: 26 year: 2021 ident: B13 article-title: The Multifunctional APE1 DNA Repair–Redox Signaling Protein as a Drug Target in Human Disease publication-title: Drug Discovery Today doi: 10.1016/j.drudis.2020.10.015 – volume: 11 year: 2017 ident: B24 article-title: APE1/Ref-1 Knockdown in Pancreatic Ductal Adenocarcinoma - Characterizing Gene Expression Changes and Identifying Novel Pathways Using Single-Cell RNA Sequencing publication-title: Mol Oncol doi: 10.1002/1878-0261.12138 – volume: 27 start-page: 388 year: 2020 ident: B46 article-title: Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis publication-title: Inflammatory Bowel Dis doi: 10.1093/ibd/izaa161 – volume: 67 year: 2010 ident: B26 article-title: Small Molecule Inhibitors of DNA Repair Nuclease Activities of APE1 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-010-0488-2 – volume: 124 year: 2021 ident: B20 article-title: Exploring Transcriptional Regulators Ref-1 and STAT3 as Therapeutic Targets in Malignant Peripheral Nerve Sheath Tumours publication-title: Br J Cancer doi: 10.1038/s41416-021-01270-8 – volume: 39 start-page: 184 year: 2020 ident: B44 article-title: Selective Antagonism of Cjun for Cancer Therapy publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-020-01686-9 – volume: 19 start-page: 3890 year: 2018 ident: B6 article-title: Advancement of NF-kappaB Signaling Pathway: A Novel Target in Pancreatic Cancer publication-title: Int J Mol Sci doi: 10.3390/ijms19123890 – volume: 9 year: 2018 ident: B18 article-title: APE1/Ref-1 Redox-Specific Inhibition Decreases Survivin Protein Levels and Induces Cell Cycle Arrest in Prostate Cancer Cells publication-title: Oncotarget doi: 10.18632/oncotarget.23493 – volume: 6 start-page: 29389 year: 2016 ident: B15 article-title: Peroxiredoxin 1 Interacts With and Blocks the Redox Factor APE1 From Activating Interleukin-8 Expression publication-title: Sci Rep doi: 10.1038/srep29389 – volume: 55 year: 2012 ident: B27 article-title: Synthesis, Biological Evaluation, and Structure-Activity Relationships of a Novel Class of Apurinic/Apyrimidinic Endonuclease 1 Inhibitors publication-title: J Med Chem doi: 10.1021/jm201537d – volume: 8 start-page: e70909 year: 2013 ident: B17 article-title: Specific Inhibition of the Redox Activity of Ape1/Ref-1 by E3330 Blocks Tnf-Alpha-Induced Activation of IL-8 Production in Liver Cancer Cell Lines publication-title: PloS One doi: 10.1371/journal.pone.0070909 – volume: 126 year: 2016 ident: B21 article-title: RelA Regulates CXCL1/CXCR2-Dependent Oncogene-Induced Senescence in Murine Kras-Driven Pancreatic Carcinogenesis publication-title: J Clin Invest doi: 10.1172/JCI86477 – volume: 290 year: 2015 ident: B29 article-title: Apurinic/apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2 publication-title: J Biol Chem doi: 10.1074/jbc.M114.621995 – volume: 117 year: 2007 ident: B22 article-title: Pancreas-Specific RelA/p65 Truncation Increases Susceptibility of Acini to Inflammation-Associated Cell Death Following Cerulein Pancreatitis publication-title: J Clin Invest doi: 10.1172/JCI29882 – volume: 13 start-page: 4510 year: 2021 ident: B4 article-title: NF-κB and Pancreatic Cancer; Chapter and Verse publication-title: Cancers (Basel) doi: 10.3390/cancers13184510 – volume: 5 start-page: 36 year: 2012 ident: B12 article-title: APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1 publication-title: Curr Mol Pharmacol doi: 10.2174/1874467211205010036 – volume: 31 year: 2011 ident: B33 article-title: Apurinic/Apyrimidinic Endonuclease 1 Regulates Inflammatory Response in Macrophages publication-title: Anticancer Res – volume: 367 year: 2018 ident: B37 article-title: Ref-1/APE1 Inhibition With Novel Small Molecules Blocks Ocular Neovascularization publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.118.248088 – volume: 6 start-page: 218 year: 2021 ident: B7 article-title: Signaling Pathways in Cancer-Associated Fibroblasts and Targeted Therapy for Cancer publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-021-00641-0 – volume: 114 year: 2017 ident: B9 article-title: Hippo Pathway Mediates Resistance to Cytotoxic Drugs publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1703096114 – volume: 9 year: 2021 ident: B19 article-title: Chemical Inhibition of Apurinic-Apyrimidinic Endonuclease 1 Redox and DNA Repair Functions Affects the Inflammatory Response via Different But Overlapping Mechanisms publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2021.731588 – volume: 52 year: 2013 ident: B39 article-title: Inhibition of Apurinic/Apyrimidinic Endonuclease I's Redox Activity Revisited publication-title: Biochemistry doi: 10.1021/bi400179m – volume: 21 year: 2010 ident: B8 article-title: Dangerous Liaisons: STAT3 and NF-kappaB Collaboration and Crosstalk in Cancer publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2009.11.005 – volume: 23 start-page: 833 year: 2018 ident: B45 article-title: Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis publication-title: Cell Stem Cell doi: 10.1016/j.stem.2018.10.013 – volume: 42 year: 2021 ident: B3 article-title: Mutations in Key Driver Genes of Pancreatic Cancer: Molecularly Targeted Therapies and Other Clinical Implications publication-title: Acta Pharmacol Sin doi: 10.1038/s41401-020-00584-2 – volume: 20 year: 2014 ident: B10 article-title: Combined Targeting of STAT3/NF-κb/COX-2/EP4 for Effective Management of Pancreatic Cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-1664 – volume: 12 start-page: 1482 year: 2021 ident: B2 article-title: KRAS Drives Immune Evasion in a Genetic Model of Pancreatic Cancer publication-title: Nat Commun doi: 10.1038/s41467-021-21736-w – volume: 21 year: 2012 ident: B5 article-title: KrasG12D-Induced IKK2/beta/NF-kappaB Activation by IL-1alpha and P62 Feedforward Loops Is Required for Development of Pancreatic Ductal Adenocarcinoma publication-title: Cancer Cell doi: 10.1016/j.ccr.2011.12.006 – volume: 19 year: 1999 ident: B42 article-title: Regulation of Interleukin-8 Gene Expression publication-title: J Interferon Cytokine Res doi: 10.1089/107999099313866 – volume: 2 year: 2021 ident: B11 article-title: APE1/Ref-1 as a Novel Target for Retinal Diseases publication-title: J Cell Signaling doi: 10.33696/Signaling.2.044 – volume: 25 start-page: 784 year: 2021 ident: B28 article-title: Combined Inhibition of Ref-1 and STAT3 Leads to Synergistic Tumour Inhibition in Multiple Cancers Using 3D and In Vivo Tumour Co-Culture Models publication-title: J Cell Mol Med doi: 10.1111/jcmm.16132 – volume: 18 year: 2019 ident: B41 article-title: Anti-Tumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-18-1166 – volume: 14 year: 2008 ident: B31 article-title: Nuclear factor-kappaB P65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1539 – volume: 132 year: 2013 ident: B23 article-title: Mdm2 Inhibitors Synergize With Topoisomerase II Inhibitors to Induce P53-Independent Pancreatic Cancer Cell Death publication-title: Int J Cancer doi: 10.1002/ijc.27916 – volume: 14 year: 2011 ident: B36 article-title: Functional Analysis of New and Novel Analogs of E3330 That Block the Redox Signaling Activity of the Multifunctional AP Endonuclease/Redox Signaling Enzyme APE1/Ref-1 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2010.3410 – volume: 10 year: 2008 ident: B34 article-title: Role of the Multifunctional DNA Repair and Redox Signaling Protein Ape1/Ref-1 in Cancer and Endothelial Cells: Small-Molecule Inhibition of the Redox Function of Ape1 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2008.2120 – volume: 12 year: 2020 ident: B1 article-title: Pancreatic Ductal Adenocarcinoma: Treatment Hurdles, Tumor Microenvironment and Immunotherapy publication-title: World J Gastrointest Oncol doi: 10.4251/wjgo.v12.i2.173 – start-page: 286 volume-title: DNA Damage, DNA Repair and Disease year: 2020 ident: B14 article-title: Basic, Translational and Clinical Relevance of the DNA Repair and Redox Signaling Protein APE1 in Human Diseases doi: 10.1039/9781839162541-00286 – volume: 36 year: 2008 ident: B16 article-title: A New APE1/Ref-1-Dependent Pathway Leading to Reduction of NF-κb and AP-1, and Activation of Their DNA-Binding Activity publication-title: Nucleic Acids Res doi: 10.1093/nar/gkn416 – volume: 9 year: 2018 ident: B43 article-title: AP-1 Confers Resistance to Anti-Cancer Therapy by Activating XIAP publication-title: Oncotarget doi: 10.18632/oncotarget.23897 – volume: 1 year: 2018 ident: B32 article-title: Determining If Double Gene Knockdown of P65 and PDK2 Increases Cytotoxicity and Radiation Sensitivity of Pancreatic Cancer Cells publication-title: Proc IMPRS doi: 10.18060/22794 – volume: 51 start-page: 695 year: 2012 ident: B38 article-title: Characterization of the Redox Activity and Disulfide Bond Formation in Apurinic/Apyrimidinic Endonuclease publication-title: Biochemistry doi: 10.1021/bi201034z – volume: 53 year: 2010 ident: B35 article-title: Design and Synthesis of Novel Quinone Inhibitors Targeted to the Redox Function of Apurinic/Apyrimidinic Endonuclease 1/Redox Enhancing Factor-1 (Ape1/Ref-1) publication-title: J Med Chem doi: 10.1021/jm9014857 |
SSID | ssj0000650103 |
Score | 2.321698 |
Snippet | Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a poor response to current treatment regimens. The multifunctional DNA... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 826617 |
SubjectTerms | Ape1 DNA repair Oncology pancreatic ductal adenocarcinoma (PDAC) redox signaling relA transcriptional factors |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals - May need to register for free articles dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JL6btOH6jQSw_urmVZlo_bzYa0sGHZJpCb0WOcGBY5rB3oH-v_64ztLLultJfik2WNJTRjzzfW-BvGPlapVc4Lotl3IpZZXsSFT1XsptjqnMpFRZ8Glufq7FJ-u8qu9kp9UU7YQA88LNyk0M5OhXep16kUeWIA0MVmuclslRW-f_uiz9sLpoZ3cEYFDIZ9SYzCiknVBGIsFOKzJp-UH_ihnq7_Txjz91TJPd9z-oQ9HkEjnw2TfcoeQHjGHi7HbfHn7OcaNjP-teUm8EVLvxOhVfGLPsmbIyrli3BDvBrhms9hs6HMU74ekmOh5V3DEQXyk_MZNt6aejtZQxUneOKbH_x7fU1YHUVXROlQBxzEk3TXp-7xFWzRa1mErH7_5iRKJdgbRJ9t3XKUWzZ3LfDVyWzed2xfsMvTxcX8LB7rMcROKtGh_nyiTJI4QNSVS5Npk2jwU086sYjkPPp7qGQBhdbKJdLgIU2qRW5FpSB9yY5CE-A145nxCUhvphZ7KK9t7jDQNNakkJhUyohN7rVTupGsnGpmbEoMWkifJemzJH2Wgz4j9mkncTsQdfyl7xdS-K4fUWz3DWh45Wh45b8ML2If7s2lxEeS9llMAFzJEjFmgUgSgVTEXg3msxuKPrNRiB2x_MCwDuZyeCXUNz3tt8ZVRbx-_D8m_4Y9ovWgZDoh37KjbnsH7xBddfZ9_yD9AmFDJUU priority: 102 providerName: Directory of Open Access Journals |
Title | RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostasis in Mouse PDAC Cells |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35402225 https://www.proquest.com/docview/2649256293 https://pubmed.ncbi.nlm.nih.gov/PMC8988139 https://doaj.org/article/98cb02dc3d834271aee89357a5bf59d2 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF7aFEIupe-qj7CFXnpQ7F2tpNWhFNdxmhYcjBuDb2JfcgxCSiUF0h_W_9cZSXbjYnooBoFXO5K9M6v5Znf0DSHvs0BHxnKk2TfcF2Gc-IkNIt8ModWYKOYZLg1ML6Lzhfi2DJd_Xo_uB7DeG9phPalFlZ_c_vj5CSb8R4w4wd8OsrJAMkLOTyS6m_g-eQB-KcZ6BtMe7HfP5RCLGnR7lXsFj8ghLoNgCLTjplo2_30Q9O9Myjuu6ewRedhjSjrqjOAxueeKJ-Rw2u-aPyW_5i4f0a81VQWd1Pi2ERgdvWxzwCmAVjoprpB2o1jRsctzTEyl8y531tW0KSmARHp6MYLGa7WuBnOX-Qy-2PKWfl-vEMqD6AwZH9YF3MSidNNm9tGZq8CpaUC09u7FURQrtJcATut1TUFuWt7Ujs5OR-O2Y_2MLM4ml-Nzvy_X4BsR8QbUa1mkGDMOQFksVCgVk84OrXJOagB6FuCAy0TiEikjw4SCj1CB5LHmWeSC5-SgKAv3ktBQWeaEVUMNPSIrdWwgDlVaBY6pQAiPDDbaSU3PZY4lNfIUYhpUbYqqTVG1aadaj3zYSlx3PB7_6PsZFb7thwzcbUNZrdJ-QqeJNHrIrQmsDASPGf7JJAhjFeosTCz3yLuNuaQwY3EbRhUORjIFCJoA0ASc5ZEXnflsb7UxP4_EO4a181t2zxTrq5YVXMKoApx_9d-Sr8kRDgIm2HHxhhw01Y17C4ir0cftSgUcvyzZcTupfgPlSS9F |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=RelA+Is+an+Essential+Target+for+Enhancing+Cellular+Responses+to+the+DNA+Repair%2FRef-1+Redox+Signaling+Protein+and+Restoring+Perturbated+Cellular+Redox+Homeostasis+in+Mouse+PDAC+Cells&rft.jtitle=Frontiers+in+oncology&rft.au=Mijit%2C+Mahmut&rft.au=Wireman%2C+Randall&rft.au=Armstrong%2C+Lee&rft.au=Gampala%2C+Silpa&rft.date=2022-03-24&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=12&rft_id=info:doi/10.3389%2Ffonc.2022.826617&rft_id=info%3Apmid%2F35402225&rft.externalDocID=PMC8988139 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |